Algorithm developed to guide evaluation, tx of motor delay

Algorithm developed to guide evaluation, tx of motor delay
An algorithm has been developed to facilitate the surveillance and screening of children for motor delays, providing guidance for initial work-up and referral, according to a clinical report published online May 27 in Pediatrics.

(HealthDay)—An algorithm has been developed to facilitate the surveillance and screening of children for motor delays, providing guidance for initial work-up and referral, according to a clinical report published online May 27 in Pediatrics.

Noting that early identification of motor delays allows for timely referral for interventions as well as diagnostic evaluations and treatment planning, Garey H. Noritz, M.D., and colleagues from a multidisciplinary neuromotor screening developed an algorithm for surveillance and screening of children with suspected motor delays.

The authors report that the algorithm was developed for the surveillance and screening for motor delays within the medical home, and provides guidance for the initial work-up and referral of the child with possible delays. Formal developmental screenings are suggested at the 9-, 18-, 30-, and 48-month well-child visits. In addition, neurological examinations should be conducted, with an emphasis on muscle tone evaluation. The report also includes initial for medical home providers. Diagnostic tests that can be used to evaluate children with motor delays include brain for those with high muscle tone and serum creatine kinase concentration measurement for those with decreased .

"The importance of pursuing diagnostic tests while concurrently referring patients to early intervention programs is emphasized," the authors write.

More information: Abstract
Full Text

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Virus drugmaker fights pediatricians' new advice

Jul 28, 2014

(AP)—A costly drug given mostly to premature babies is at the center of a clash between the manufacturer and the leading U.S. pediatrician's group, which recommends scaling back use of the medicine.

User comments